Alexithymia and interleukin variations in somatoform disorder

NeuroImmunoModulation

Volumn 14, Issue 5, 2007, Pages 235-242

  Pedrosa Gil, Francisco ^a,e   Nickel, Marius ^b,c   Ridout, Nathan ^d   Schwarz, Markus J ^a   Schoechlin, Claudia ^a   Schmidmaier, Ralf ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d ASTON UNIVERSITY   (United Kingdom)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Alexithymia; Interleukin; Somatoform disorders

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 6;

ADULT; ALEXITHYMIA; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSTIMULATION; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SCREENING FOR SOMATOFORM SYMPTOMS SCALE; SOMATOFORM DISORDER; SYMPTOMATOLOGY; TH1 CELL; TH2 CELL; TORONTO ALEXITHYMIA SCALE;

AFFECTIVE SYMPTOMS; BIOLOGICAL MARKERS; IMMUNE SYSTEM DISEASES; IMMUNOGLOBULIN E; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-6; INTERLEUKINS; MASS SCREENING; NEUROPSYCHOLOGICAL TESTS; QUESTIONNAIRES; SOMATOFORM DISORDERS; TH1 CELLS; TH2 CELLS; UP-REGULATION;

EID: 40349091888     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112048     Document Type: Article

References (55)

1. Ustun TB, Sartorius N (eds): Mental Illness in General Health Care. Chichester, John Wiley, 1995.
2. Swartz M, Blazer D, Georg L, Landerman R: Somatization disorder in a community population. Am J Psychiatry 1986;143:1403-1408.
3. Escobar JI, Waitzkin H, Silver RC: Abridged somatization: a study in primary care. Psychosom Med 1998;60:466-472.
4. Barsky AJ, Orav E, Bates DW: Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch Gen Psychiatry 2005;62:903-910.
5. Bach M, Bach D: Predictive value of alexithymia: a prospective study in somatizing patients. Psychother Psychosom 1995;64:43-48.
6. Bankier B, Aigner M, Bach M: Alexithymia in DSM-IV disorder. Comparative evaluation of somatoform disorder, panic disorder, obsessive-compulsive disorder, and depression. Psychosomatics 2001;42:235-240.
7. Sifneos PE: The prevalence of 'alexithymic' characteristics in psychosomatic patients. Psychother Psychosom 1973;22:255-262.
8. Naatanen P, Rynamen A, Keltikangas-Jarvinen L: The influence of alexithymia characteristics on the self-perception and facial expression of physiological stress state. Psychother Psychosom 1999;68:252-262.
9. Wise TN, Mann LS, Sheridan MJ: Relationship between alexithymia, dissociation and personality in psychiatric outpatients. Psychother Psychosom 2000;69:123-127.
10. Lundh LG, Simonsson-Sarnecki M: Alexithymia, emotion, and somatic complaints. J Pers 2001;69:483-510.
11. Minami M, Katayama T, Satoh M: Brain cytokines and chemokines: roles in ischemic injury and pain. J Pharmacol Sci 2006;100:461-470.
12. Rief W, Pilger F, Ihle D, Bosmans E, Egyed B, Maes M: Immunological differences between patients with major depression and somatization syndrome. Psychiatry Res 2001;105:165-174.
13. Todarello O, Casamassima A, Marinaccio M, La Pesa MW, Caradonna L, Valentino L, Marinaccio L: Alexithymia, immunity and cervical intraepithelial neoplasia: a pilot study. Psychother Psychosom 1994;61:199-204.
14. Todarello O, Casamassima A, Daniele S, Marinaccio M, Fanciullo F, Valentino L, Tedesco N, Wiesel S, Simone G, Marinaccio L: Alexithymia, immunity and cervical intraepithelial neoplasia: replication. Psychother Psychosom 1997;66:208-213.
15. Dewaraja R, Tanigawa T, Araki S, Nakata A, Kawamura N, Ago Y, Sasaki Y: Decreased cytotoxic lymphocyte counts in alexithymia. Psychother Psychosom 1997;66:83-86.
16. Corcos M, Guilbaud O, Paterniti S, Curt F, Hjalmarsson L, Moussa M, Chambry J, Loas G, Chaout G, Jeammet P: Correlation between serum levels of interleukin-4 and alexithymia scores in healthy female subjects: preliminary findings. Psychoneuroendocrinology 2004;29:686-691.
17. Kelly-Welch A, Hanson EM, Keegan AD: Interleukin-4 (IL-4) pathway. Sci STKE 2005;293:9.
18. Dantzer R: Somatization: a psychoneuroimmune perspective. Psychoneuroendocrinology 2005;30:947-952.
19. Guilbaud O, Corcos M, Hjalmarsson L, Loas G, Jeammet P: Is there a psychoneuroimmunological pathway between alexithymia and immunity? Immune and physiological correlates of alexithymia. Biomed Pharmacother 2003;57:292-295.
20. Kupfer J, Brosig B, Brahler E: Testing and validation of the 26-item Toronto Alexithymia Scale in a representative population sample. Z Psychosom Med Psychother 2000;46:368.
21. Kupfer J, Brosig B, Brähler E: Toronto-Alexithymie-Skala-26, Deutsche Version. Göttingen, Hogrefe Verlag, 2001.
22. Hiller W, Zaudig M, Mombour W: International Diagnostic Checklists for ICD-10 and DSM-IV (Handbook). Seattle, Hogrefe & Huber, 1996.
23. Rief W, Hiller W, Heuser J: SOMS - Das Screening für Somatoforme Störungen. Manual zum Fragebogen. Bern, Hans Huber Verlag, 1997.
24. Taylor GJ, Bagby RM, Parker JDA: The Revised Toronto Alexithymia Scale: some reliability, validity, and normative data. Psychother Psychosom 1992;57:34-41.
25. Derogatis LR: SCL-90-R. Self-report symptom inventory; in Collegium Internationale Psychiatriae Scalarum (ed): Internationale Skalen für Psychiatrie. Weinheim, Beltz Verlag, 1994.
26. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
27. Beck AT, Ward CH, Mendelson M, Mock F, Erbaugh F: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
28. Wolf RE, Brelsford WG: Soluble interleukin-2-receptors in systemic lupus erythematosus. Arthritis Rheum 1988;31:729-735.
29. De Gucht V, Heiser W: Alexithymia and somatisation: quantitative review of the literature. J Psychosom Res 2003;54:425-434.
30. Kidd P: Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 2003;8:223-246.
31. Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M, Wiktorowicz K: Indicators of immune activation in major depression. Psychiatry Res 1996;64:161-167.
32. Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR: Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:899-905.
33. Waldmann TA: The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 1993;14:264-270.
34. Fernandez-Botran R: Soluble cytokine receptors: their role in immunoregulation. FASEB J 1991;5:2567-2574.
35. Parker JDA, Taylor GJ, Bagby R: The 20-item Toronto Alexithymia Scale-III. Reliability and factorial validity in a community population. J Psychosom Res 2003;55:269-275.
36. Lane RD, Sechrest L, Riedel R: Sociodemographic correlates of alexithymia. Compr Psychiatry 1998;39:377-385.
37. Loas G, Corcos M, Stephan P, Pellet J, Bizouard P, Venisse JL: Factorial structure of the 20-item Toronto Alexithymia Scale. Confirmatory factorial analyses in nonclinical and clinical samples. J Psychosom Res 2001;50:255-261.
38. Martin JB, Pihl RO: Influence of alexithymic characteristics on physiological and subjective stress responses in normal individuals. Psychother Psychosom 45:66-77.
39. Friedlander L, Lumley MA, Farchione T, Doyal G: Testing the alexithymia hypothesis: physiological and subjective responses during relaxation and stress. J Nerv Ment Dis 1997;185:233-239.
40. Stone LA, Nielson KA: Intact physiological response to arousal with impaired emotional recognition in alexithymia. Psychother Psychosom 2001;70:92-102.
41. DeRijk R, Michelson D, Karp B, Petrides J, Galliven E, Deuster P, Paciott, G, Gold PW, Sternberg EM: Exercise and circadian rhythm-induced variations in plasma cortisol differentially regulate interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-β(TNF-α) production in humans: high sensitivity of TNF-α and resistance of IL-6. J Clin Endocrinol Metab 1997;82: 2182-2192.
42. Zhou D, Kusnecov AW, Shurin MR, DePaoli M, Rabin BS: Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic-pituitary-adrenal axis. Endocrinology 1993;133: 2523-2530.
43. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP: The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127-137.
44. Henry JP, Haviland MG, Cummings MA, Anderson DL, Nelson JC, MacMurray JP, McGhee WH, Hubbard RW: Shared neuroendocrine patterns of post-traumatic stress disorder and alexithymia. Psychosom Med 1992;54:407-415.
45. Spitzer C, Brandl S, Rose HJ, Nauck M, Freyberger HJ: Gender-specific association of alexithymia and norepinephrine/cortisol ratios. A preliminary report. J Psychosom Res 2005;59:73-76.
46. Finset A, Graugaard PK, Holgersen K: Salivary cortisol response after a medical interview: the impact of physician communication behaviour, depressed affect and alexithymia. Patient Educ Couns 2006;60:115-124.
47. Alfvén G, de la Torre B, Uvnas-Moberg K: Depressed concentrations of oxytocin and cortisol in children with recurrent abdominal pain of non-organic origin. Acta Paediatr 1994;83:1076-1080.
48. Chrousos GP, Gold PW: A healthy body in a healthy mind - and vice versa - the damaging power of 'uncontrollable' stress. J Clin Endocrinol Metab 1998;83: 1842-1845.
49. Ehlert U, Gaab J, Heinrichs M: Psychoneuroendocrinological contributions to the etiology of depression, posttraumatic stress disorder, and stress-related bodily disorders: the role of the hypothalamus-pituitary-adrenal axis. Biol Psychol 2001;57:141-152.
50. Yoshida T, Kaneshi T, Shimabukuro T, Sunagawa M, Ohta T: Serum C-reactive protein and its relation to cardiovascular risk factors and adipocytokines in Japanese children. J Clin Endocrinol Metab 2006;91:2133-2137.
51. Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C: The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis 2005;183:308-315.
52. Oeser A, Chung CP, Asanuma Y, Avalos I, Stein CM: Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 2005;52:3651-3659.
53. Pollmächer T, Haack M, Schuld A, Kraus T, Hinze-Selch D: Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res 2000;34:369-382.
54. Hinze-Selch D, Schuld A, Kraus T, Kühn M, Uhr M, Haack M, Pollmächer T: Effects of antidepressants on weight and on the plasma levels of leptin, TNF-α and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 2000;23:13-19.
55. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kühn M, Schuld A, Pollmächer T: Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999;33:407-418.